L. Corazza

Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study.

Luca Quartuccio, S. Salvin, L. Corazza, Saviana Gandolfo et autres

OBJECTIVES: Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody, appeared effective in Sjögren's syndrome (SS) in the phase II open-label 52-week BELISS study. Herein, the follow-up after the end of the BELISS study and suspension of the drug was reported in order …

it (code pays fourni par la source)

Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients

Soledad Retamozo, H. Gheitasi, Luca Quartuccio, Belchin Kostov et autres

OBJECTIVE: To evaluate the fulfilment of classification criteria for cryoglobulinaemic vasculitis (CV) at diagnosis in a large cohort of patients with primary SS and their correlation with poor outcomes. METHODS: We included 515 consecutive patients tested for serum cryoglobulins who fulfilled the …

it, es (code pays fourni par la source)

Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study

Luca Quartuccio, Francesca Zuliani, L. Corazza, Patrizia Scaini et autres

it (code pays fourni par la source)

Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution

Luca Quartuccio, Chiara Baldini, Elena Bartoloni, Roberta Priori et autres

it (code pays fourni par la source)

AB0586 Persistent Rather Than Fluctuating Serum Cryoglobulins are Associated with Cryoglobulinemic Vasculitis in Primary SjÖgren's Syndrome, and Related to the Risk of Lymphoma

Luca Quartuccio, L. Corazza, Saviana Gandolfo, Salvatore De Vita

it (code pays fourni par la source)

OP0274 Cryoglobulinemic Vasculitis and Primary sjögren's Syndrome are Independent Risk Factors for Lymphoma in a Large Worldwide Population of Patients with Positive Serum Cryoglobulins

Luca Quartuccio, L. Corazza, Manuel Ramos‐Casals, Soledad Retamozo et autres

it, es, Égypte, gr, fr, si, jp, us (code pays fourni par la source)

THU0394 Worsening of Systemic Activity and Increases of B-Cell Biomarkers in sjögren's Syndrome after Suspension of Belimumab Treatment: Long-Term Follow-Up After the End of the Beliss Study

Luca Quartuccio, S. Salvin, L. Corazza, Saviana Gandolfo et autres

it (code pays fourni par la source)

THU0402 Increased Expression of Baff Receptor on B Cells May be Implicated in Delayed Response in Systemic Lupus Erythematosus Patients Under Belimumab Therapy

Luca Quartuccio, G. De Marchi, Francesca Maria Rossi, Francesca Zuliani et autres

it (code pays fourni par la source)

Validation of the classification criteria for cryoglobulinaemic vasculitis

Luca Quartuccio, Miriam Isola, L. Corazza, Manuel Ramos‐Casals et autres

OBJECTIVE: The aim of this study was to validate the classification criteria for cryoglobulinaemic vasculitis (CV). METHODS: Twenty-three centres were involved. New patients with CV (group A) and controls, i.e. subjects with serum cryoglobulins but lacking CV based on the gold standard …

it, us (code pays fourni par la source)

OP0228 Rituximab Monotherapy of Severe Hcv-Related Cryoglobulinemic Vasculitis for More than 2 Years: Follow-Up of A Randomized Controlled Multicentre Study

Luca Quartuccio, Francesca Zuliani, L. Corazza, Patrizia Scaini et autres

it (code pays fourni par la source)

SAT0175 Results of the Classification Criteria for Cryoglobulinemic Vasculitis Validation Study

Salvatore De Vita, Luca Quartuccio, Miriam Isola, L. Corazza et autres

it, us, es, Égypte, gr, fr, si, jp (code pays fourni par la source)

Validation Study Of The International Classification Criteria For TheCryoglobulinemic Vasculitis

Luca Quartuccio, Miriam Isola, L. Corazza, Soledad Retamozo et autres